Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Accounts Payables (2019 - 2025)

Avidity Biosciences' Accounts Payables history spans 7 years, with the latest figure at $12.4 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 46.59% year-over-year to $12.4 million; the TTM value through Dec 2025 reached $12.4 million, up 46.59%, while the annual FY2025 figure was $12.4 million, 46.59% up from the prior year.
  • Accounts Payables reached $12.4 million in Q4 2025 per RNA's latest filing, up from $9.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $54.2 million in Q1 2025 to a low of $3.9 million in Q2 2025.
  • Average Accounts Payables over 5 years is $24.6 million, with a median of $23.5 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: surged 140.71% in 2022, then crashed 90.44% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $14.1 million in 2021, then skyrocketed by 131.25% to $32.6 million in 2022, then increased by 5.43% to $34.3 million in 2023, then tumbled by 75.36% to $8.5 million in 2024, then skyrocketed by 46.59% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Accounts Payables are $12.4 million (Q4 2025), $9.6 million (Q3 2025), and $3.9 million (Q2 2025).